Loading...
XSHG
688050
, Last price  
Name

Eyebright Medical Technology Beijing Co Ltd

Chart & performance

D1W1MN
XSHG:688050 chart
P/E
—
P/S
—
EPS
2.55
Vol. 1Y
—
Shs. 5Y
3.63%
Rev. 5Y
40.27%
Div Yld LY
—
Div Yld TTM
—
Revenues
1.48b
+5.15%
43,529,11174,811,083126,972,753195,197,499273,048,714433,070,741579,496,908951,177,1001,410,022,4581,482,702,700
Net income
268m
-30.96%
-1,396,586-4,107,90220,308,17666,685,11396,558,259171,344,224232,693,992303,978,314388,402,957268,170,112
CFO
369m
+6.15%
04,150,31431,820,01250,493,599123,354,371219,296,419250,132,490226,266,091347,754,061369,147,116
Dividend
Jun 22, 20260.32 /sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Eye Bright Medical Technology Co., Ltd., established in 2010 in Beijing, China, specializes in crafting a diverse array of ophthalmic medical solutions. The company's extensive product line is geared towards addressing various ocular conditions and visual impairments, encompassing surgical implants, specialized instruments, and diagnostic equipment, as well as optometric lenses and pharmaceutical eye drops. These innovations are developed to provide treatment for a range of eye diseases, notably cataracts, glaucoma, and refractive errors, among other ophthalmic issues.
IPO date
Jul 29, 2020
Employees
Domiciled in
CN
Incorporated in
CN
Headquarters & legal address
兴昌路9号
昌平区, BJ 102200
CN
Other language
Eyebright Medical Technology (Beijing) Co., Ltd.

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT